Kornimate/medical-research-clean huggingface dataset:
study evaluating the effectiveness of treatment with vista care®, in arterial ulcers of the lower extremities

Conditions: Wound Heal

Summary: the prevalence of chronic wounds is around 2 million people in france per year. a chronic wound is a wound that has been evolving for more than 6 weeks. the main causes are: venous causes, arterial causes and microcirculatory causes. in some aetiologies (particularly arterial causes), there is no radical therapeutic solution (no possibility of revascularisation) and the wounds are often difficult to treat and may even eventually lead to amputation. the recommendations for treating wounds are (in addition to carrying out an etiological treatment when possible) to carry out mechanical detersion and to maintain a moist wound environment. in addition to various medical devices such as dressings, adjuvant treatments that are not specific to the etiology of the wound, such as electrotherapy, negative pressure therapy or other devices such as the vistacare®, are indicated in france.

prospective, open-label, multi-centre study evaluating the performance of the vistacare® wound healing device in routine practice.

Eligibility criteria:
inclusion criteria: * -patient able and willing to comply with the requirements of the including hospitalization for up to 15 days. * patient whose wound to be studied is located in a location compatible with the use of vistacare®, namely the leg including the knee but excluding the upper thigh * agreement of the study no-objection form * age greater than or equal to 18 years * patient affiliated to a social security scheme exclusion criteria: * -patient with general signs of infection at the time of inclusion (fever, lymphangitis, pus ...). patient with active smoking subject under guardianship or deprived of liberty failure to obtain patient consent
a multi-center study a single iv infusion of allogeneic mpcs in patients with rheumatoid arthritis and incomplete response to at least one tnfα inhibitor

Conditions: Rheumatoid Arthritis

Summary: study is a double-blind, randomized, placebo controlled, dose escalating study. the primary objective of this study is to evaluate the safety, tolerability and feasibility of a single intravenous infusion of allogeneic mesenchymal precursor cells (mpcs) compared to placebo at 12 weeks post-infusion in the treatment of patients with active rheumatoid arthritis (ra) who have received methotrexate +/- other dmards for at least 6 months prior to screening and who have had an incomplete response to at least one tnf-alpha inhibitor.


Eligibility criteria:
inclusion criteria: * males and females ages 18-80 years old * active rheumatoid arthritis (ra) disease as per 2010 acr/eular classification criteria for the diagnosis of ra. * must be positive for rheumatoid factor and/or anti-cyclic citrullinated peptide (anti-ccp3) but without extra-articular disease or functional limitation * patient with active ra defined as: * ≥ 4 tender joint count (tjc) 28 joint count at screening and * ≥ 4 swollen joint count (sjc) count 28 joint count at screening * esr ≥ 28 mm/hr or hscrp \>2.0 mg/l * patient has been taking mtx for at least 4 months with dose and route of administration stable for at least 8 weeks prior to screening * patient has had an inadequate response to at least one tnfα inhibitor with last dose at least 6 weeks prior to screening * use of oral dmard (sulfasalazine, hydroxychloroquine, chloroquine and leflunomide) is permitted but must be stable for at least 3 months prior to screening exclusion criteria: * pregnant women or women who are breastfeeding. * other investigational therapy received within 8 weeks or five half-lives (whichever is longer) prior to screening (except as in exclusion #13). * known or suspected alcohol or drug abuse within three years preceding screening. * autoimmune disease other than ra (such as systemic lupus erythematosus (sle), mixed connective tissue disease, scleroderma, polymyositis/dermatomyositis, vasculitis) * history of or current inflammatory joint disease other than ra (such as tophaceous gout, reactive arthritis, psoriatic arthritis, ankylosing spondylitis or other spondyloarthropathy, lyme disease). patients primarily diagnosed with osteoarthritis are excluded. * bedridden or confined to a wheelchair or patients with \> 3 arthroplasties due to ra. * history of diagnosed and/or treated malignancy with no evidence of recurrence in past 5 years * surgical procedures planned to occur during the trial (these patients may be rescreened following completion of and recovery from the surgical procedure). * use of tnfα inhibitor for treatment of ra at time of screening or within the 6 weeks prior to screening. * prior use of biologic agent for treatment of ra within 6 weeks prior to screening
prolongation of progesterone supplementation in antagonist cycles and pregnancy outcomes

Conditions: Infertility

Summary: the objective of this study is to evaluate the effect of the prolongation of luteal support on the ongoing pregnancy rate (beyond 12 weeks of gestation )in recfsh/gnrh antagonist cycles.


Eligibility criteria:
inclusion criteria: * age equal or less than 39 * body mass index between 18-29 kg/m2 * presence of both ovaries * basal hormonal values on day 2 of the cycle * embryotransfer day3 or day5 * 1 to 3 cycles exclusion criteria: * endometriosis stage 3 * polycystic ovarian syndrome * frozen or testicular sperm

Keywords: progesterone antagonist rec fsh ivf pregnancy
reliability and validity of the traumatic injuries distress scale to turkish

Conditions: Musculoskeletal Injury; Trauma Injury

Summary: the traumatic injuries distress scale is a patient-reported measure that assesses suffering following non-catastrophic musculoskeletal injuries. the original english version demonstrated acceptable accuracy in predicting recovery trajectories up to 12 months later. this study aimed to determine the cultural adaptation, validity and reliability of the turkish version of tids-tr in young and physically active patients with hip pain.

the traumatic injuries distress scale (tids) is commonly used to measure methods of coping with various forms of traumatic injuries. tids is a self-report questionnaire developed by david m. walton et al. in 2016 to assess the magnitude of stress experienced as a result of recent musculoskeletal trauma. it is administered between 2 days and 4 weeks after injury and is used to estimate the likelihood of recovery within 6 to 12 months. each item in the tids questionnaire, which consists of 12 items, is scored as 0, 1, or 2, and the total score is at least 0 and at most 24. the total tids score is interpreted as low risk (≤ 3), medium or unknown risk (4 to 10), and high risk (≥ 11) according to the score obtained. tids consists of three subscales: 1) uncontrolled pain (4 items), 2) negative affect (6 items), and 3) intrusion/hyperarousal (2 items). each of the subscales has guiding features for clinicians to determine treatment priorities such as pain management, cognitive or psychological intervention, and stress management techniques. it is recommended that when the uncontrolled pain subscale score is 3 and above, the applications should be aimed at symptom control, when the negative affect score is 3 and above, the applications should be aimed at correcting negative mood, and when the intrusion/hyperarousal score is 1 and above, the applications should be aimed at treating anxiety and post-traumatic stress disorder. the questionnaires validity and reliability were examined, and good findings were found, leading to the tools widespread use. the purpose of this study was to translate and culturally adapt the original english version of the tids into turkish, as well as to evaluate the instruments validity and reliability in patients with traumatic musculoskeletal injury.

Eligibility criteria:
inclusion criteria: * at least 18 years old, * having good reading and writing skills in turkish, * having suffered a traumatic musculoskeletal injury that does not require surgery or inpatient treatment * at least 2 and at most 4 weeks have passed since the injury exclusion criteria: * those with organ disease * those with blood clotting disorders * those with neuromuscular disorders * those with rheumatoid diseases * those with cancer * those with systemic diseases such as uncontrollable psychopathology

Keywords: tids reliability validity tids-tr
study to determine the efficacy of uproleselan (gmi-1271) in combination with chemotherapy to treat relapsed/refractory acute myeloid leukemia

Conditions: Acute Myeloid Leukemia

Summary: this study will evaluate the efficacy of uproleselan (gmi-1271), a specific e-selectin antagonist, in combination with chemotherapy to treat relapsed/refractory aml, compared to chemotherapy alone. the safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory aml


Eligibility criteria:
inclusion criteria: * ≥18 years and ≤75 years in age * patients with relapsed or refractory aml * no more than one prior stem cell transplant * has not received the chemotherapy regimen to be used for induction on this trial * is considered medically eligible to receive the chemotherapy regimen to be used for induction on this trial exclusion criteria: * patients with acute promyelocytic leukemia, acute leukemia of ambiguous lineage (biphenotypic leukemia), chronic myeloid leukemia with myeloid blast crisis, or secondary refractory aml. * active signs or symptoms of cns involvement by malignancy. * stem cell transplantation ≤4 months prior to dosing. * any immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing. * prior use of g-csf, cm-csf or plerixafor within 7 days of dosing. * inadequate organ function. * abnormal liver function. * known active infection with hepatitis a, b, or c, or human immunodeficiency virus. * moderate kidney dysfunction (glomerular filtration rate \<45 ml/min). * uncontrolled acute life-threatening bacterial, viral, or fungal infection. * clinically significant cardiovascular disease. * major surgery within 4 weeks of dosing.

Keywords: acute myeloid leukemia aml relapsed aml refractory aml
comparison of the effectiveness of an adapted physical activity program in a dedicated structure to a self-program in patients in chronic phase of a stroke

Conditions: Stroke

Summary: this is a prospective, randomized, controlled, two parallel arms, single-blind pilot study. in this design, all included patients in the chronic phase of a stroke will receive both modes of physical activity. this study includes patients over 18 years of age with spastic hemiparesis sequelae of a first unilateral hemispheric stroke older than 6 months and able to walk for 6 minutes. the non-inclusion criteria were the inability to walk without human assistance (with or without technical aids), the existence of cognitive disorders compromising informed consent, in particular the inability to understand the objective and the modalities of the protocol, the inability to communicate with the examiners, and the presence of an additional neurological disorder or a pathology contraindicating the practice of physical activity. the primary endpoint is based on daily activity measurement by measuring the number of steps per day, collected over the duration of the study, via a stepwatch™ device. secondary end points involve a written physical activity report, assessment of walking ability (via walking-test 6, heart rate, and blood pressure), a measure of perceived exertion, stroke-specific quality of life, balance, and motivation to perform physical activity.


Eligibility criteria:
inclusion criteria: * age greater than 18 years * left or right spastic hemiparesis after a first hemorrhagic or ischemic unilateral stroke older than 6 months * walking possible for 6 minutes exclusion criteria: * inability to walk without human assistance (with or without technical aids) * cognitive impairment that compromises informed consent, including inability to understand the purpose and terms of the protocol * inability to communicate * presence of an additional neurological disorder * medical conditions that contraindicate physical activity, such as an unbalanced cardiovascular or respiratory condition * concurrent participation in another clinical research project
cervical cancer screening in cameroon

Conditions: Cervical Cancer; HIV/AIDS

Summary: human immunodeficiency virus-infected (hiv\[+\]) women have a several-fold increased risk of invasive cervical cancer (icc) as well as increased risk of cervical pre-cancer. in low- and middle-income countries (lmics), icc is the 1st or 2nd most common cause of cancer and cancer-related death in women. rates of icc and icc-related mortality are particularly high in sub-saharan africa, which also has the highest rates of hiv infection in the world. although prophylactic hpv vaccines may be the optimal cervical cancer prevention strategy, 2-3 generations of at-risk hiv\[+\] and hiv\[-\] women are already highly exposed to human papillomavirus (hpv) and would not benefit from (and will not be immunized with) hpv vaccine. thus cervical cancer screening is needed for the foreseeable future. however, pap testing is expensive and requires a complex clinical and lab infrastructure that does not generally exist in lmics; strategies based on high-risk hpv (hrhpv) testing or visual inspection after acetic acid (via) are promising but are either too non-specific, leading to over-referral for colposcopy or over-treatment, or are too insensitive, respectively. thus, inexpensive, easily implemented, and effective cervical cancer screening methods are greatly needed in sub-saharan africa, especially for hiv\[+\] women. this cervical cancer screening study of 1,200 women (800 hiv\[+\] and 400 hiv\[-\] women), aged 25-59 years, living in cameroon, utilized our existing research site. the investigators evaluated screening tests (hrhpv testing, via and pap), traditional triage tests (hpv16/18/45 detection, via, pap), and promising new biomarkers for triage (ki-c67, top2a, cdkn2a, and hpv viral load) of screen-positive women. all screen positives underwent rigorous disease ascertainment to obtain unbiased estimates of sensitivity, specificity, and positive and negative predictive value. the goal of this study was to establish the foundation and capacity for future studies designed to reduce the burden of hpv-associated cancers in the cameroon population. it will inform cameroon and other countries with high hiv burdens on the best strategies for cervical cancer screening in their hiv\[+\] and hiv\[-\] women.


Eligibility criteria:
inclusion criteria: * women living in limbe town and neighborhood * confirmed to be hiv\[+\] or hiv\[-\] * have never undergone cervical cancer screening, with no history of icc * willing and able to competently understand and provide written, informed paper-based consent * women who are having a menstrual period will be deferred for 2 weeks from participating in the study exclusion criteria: * pregnant women * women with signs of abnormalities * non-menstrual bleeding suggestive of icc * without a cervix because they have undergone hysterectomy * based on the judgment of the clinicians not sufficiently healthy to participate in a research study

Keywords: hiv hpv screening cervical cancer self sampling human papillomavirus
oxygen requirements and use in patients with covid-19 in lmics

Conditions: Covid19; COVID-19 Pneumonia

Summary: this observational cohort study will enroll patients in lmics with suspected or confirmed covid-19 on oxygen or deemed to require oxygen therapy based on objective criteria. demographics and risk factor information will be collected from participants. participants will be followed for 7 days or until outcome (hospital discharge or death). facility level metrics on oxygen availability will also be collected at the beginning of site enrolment.

the covid-19 pandemic has highlighted, more than ever, the acute need for scale up of oxygen therapy. who has provided an inventory tool to quantify facility-level provision of infrastructure to deliver oxygen therapy. however, data on the use of oxygen therapy at the patient-level remains lacking. this observational cohort study will enroll patients in lmics with suspected or confirmed covid-19 on oxygen or deemed to require oxygen therapy based on objective criteria. demographics and risk factor information will be collected from participants. participants will be followed for 7 days or until outcome (hospital discharge or death). facility level metrics on oxygen availability will also be collected at the beginning of site enrolment.

Eligibility criteria:
inclusion criteria: 1. suspected sars-cov-2 infection as determined by treating clinical provider, or confirmed sars-cov-2 infection confirmed virologically in the lab by rt-pcr via nasopharyngeal or oropharyngeal sample or by sars-cov-2 ag-rdts that meet the minimum performance requirements of ≥80% sensitivity and ≥97% specificity compared to a naat reference assay. 2. receiving supplemental oxygen or showing clinical evidence of need for supplemental respiratory support as reflected in a respiratory rate ≥30 breaths per minute or an spo2 ≤ 90%, spo2 \< 94 % if any emergency signs are present 3. admitted to health care facility exclusion criteria: 1. is not receiving oxygen or does not have clinical criteria for oxygen treatment specified above oxygen therapy 2. does not have suspected or confirmed covid-19 (as per criteria above) 3. patient younger than 12 years of age 4. lack of commitment to full supportive care

Keywords: oxygen covid-19
etiology of the platelet-cancer metastatic pathway - a study of inflammatory markers, platelet characteristics and metastatic surrogates in cancer patients and controls

Conditions: Neoplasm

Summary: the purpose of this research study is to understand if platelets in the blood become more active during cancer and specially advanced stages of cancer, in the future the investigators want to see if reducing platelet activity can improve survival in advanced cancer.

hypotheses for proposed study platelet reactivity as measured by percentage aggregation in response to agonists such as adp is increased in patients with metastatic cancer compared to age sex and ethnicity matched controls. platelet activation as measured by release of cytokines and vasoactive substances such as vegf, tgf-beta, and pdgf is increased in patients with metastatic cancer compared to age sex and ethnicity matched controls. study design: single center matched case control design; matching variables are age, sex and ethnicity inclusion criteria cases: 25 adult patients (\>18 years old) with any form of metastatic or advanced stage (tnm stage iii or equivalent) solid adenocarcinoma including breast, colon, and lung cancer will be eligible for inclusion in this study with no restrictions related to previous chemotherapy, radiotherapy, biological therapy or surgical management at the time of enrollment or in the past., although we will prefer to recruit them prior to initiating chemotherapy. controls: 25 patients will be selected based on age (+/- 5 years), sex and ethnicity matches from the outpatient medicine clinic at sinai hospital, as well as the sinai community care clinic. exclusion criteria: thrombocytopenia, defined as a platelet count of \<100,000 at the time of recruitment of in the last available laboratory data history of known bleeding disorder or known platelet dysfunction patients on antiplatelet treatment or anticoagulant therapies at the time of enrollment or 10 days prior to testing ckd stage iv or greater

Eligibility criteria:
inclusion criteria: cases: 25 adult patients (\>18 years old) with any form of metastatic or advanced stage (tnm stage iii or equivalent) solid adenocarcinoma including breast, colon, and lung cancer will be eligible for inclusion in this study with no restrictions related to previous chemotherapy, radiotherapy, biological therapy or surgical management at the time of enrollment or in the past., although we will prefer to recruit them prior to initiating chemotherapy. controls: 25 patients will be selected based on age (+/- 5 years), sex and ethnicity matches from the outpatient medicine clinic at sinai hospital, as well as the sinai community care clinic. exclusion criteria: * thrombocytopenia, defined as a platelet count of \<100,000 at the time of * recruitment of in the last available laboratory data * history of known bleeding disorder or known platelet dysfunction * patients on antiplatelet treatment or anticoagulant therapies at the time of enrollment or 10 days prior to testing * ckd stage iv or greater

Keywords: platelet activation metastasis
the effects of inspiratory muscle training on diaphragm thickness, inspiratory muscle strength and exercise capacity in individuals with sarcopenia

Conditions: Sarcopenia

Summary: sarcopenia, according to ewgsop2(european working group on sarcopenia in older people-2019), is a progressive and generalised skeletal muscle disorder that is associated with increased likelihood of adverse outcomes including falls, fractures, physical disability, and mortality. changes in muscle strength and muscle mass that occur with aging are not only limited to the skeletal muscles surrounding the axial and appendicular skeleton, but also occur in the respiratory muscles. with aging, respiratory muscle strength decreases, muscle mass decreases, and respiratory functions decline. in sarcopenic individuals; maximum inspiratory pressure (mip), maximum expiratory pressure (mep) and diaphragm muscle thickness values were found to be significantly lower. it is known that exercise is the most effective and valid way to treat sarcopenia. considering the positive effects of imt (inspiratory muscle training) on both respiratory and physical parameters in the elderly population, we think that these changes can also be observed in sarcopenic individuals. therefore, the aim of this study is to investigate the effects of inspiratory muscle training on diaphragm thickness, inspiratory muscle strength, and exercise capacity in sarcopenic individuals.


Eligibility criteria:
inclusion criteria: * people who are diagnosed with confirmed sarcopenia or severe sarcopenia according to ewgsop2 (european working group on sarcopenia in older people-2019) * getting a score of 24 or higher on the mini-mental state test exclusion criteria: * presence of chronic lung and/or cardiovascular disease * presence of severe orthopedic diseases which may affect participants' mobility * presence of uncontrollable hypertension and/or diabetes.

Keywords: inspiratory muscle training diaphragm thickness respiratory sarcopenia sarcopenia